Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Nutr Biochem ; 32: 39-45, 2016 06.
Artigo em Inglês | MEDLINE | ID: mdl-27142735

RESUMO

Palmitic acid (C16:0) and TLR2 ligand induce, but docosahexaenoic acid (DHA) inhibits monocyte activation. C16:0 and TLR2 or TLR4 ligand induce certain ER stress markers; thus, we determined whether ER stress induced by these agonists is sufficient to induce monocyte activation, and whether the ER stress is inhibited by DHA which is known to inhibit C16:0- or ligand-induced TLR activation. Monocyte activation and ER stress were assessed by TLR/inflammasome-induced IL-1ß production, and phosphorylation of IRE-1 and eIF2 and expression of CHOP, respectively in THP-1 cells. TLR2 ligand Pam3CSK4 induced phosphorylation of eIF2, but not phosphorylation of IRE-1 and CHOP expression. LPS also induced phosphorylation of both IRE-1 and eIF2 but not CHOP expression suggesting that TLR2 or TLR4 ligand, or C16:0 induces different ER stress responses. C16:0-, Pam3CSK4-, or LPS-induced IL-1ß production was inhibited by 4-phenylbutyric acid, an inhibitor of ER stress suggesting that IL-1ß production induced by these agonists is partly mediated through ER stress. Among two ER stress-inducing molecules, thapsigargin but not tunicamycin led to the expression of pro-IL-1ß and secretion of IL-1ß. Thus, not all types of ER stress are sufficient to induce inflammasome-mediated IL-1ß secretion in monocytes. Although both C16:0 and thapsigargin-induced IL-1ß secretion was inhibited by DHA, only C16:0-mediated ER stress was responsive to DHA. These findings suggest that the anti-inflammatory effects of DHA are at least in part mediated through modulating ER homeostasis and that the propensity of ER stress can be differentially modulated by the types of dietary fat we consume.


Assuntos
Anti-Inflamatórios não Esteroides/metabolismo , Ácidos Docosa-Hexaenoicos/metabolismo , Estresse do Retículo Endoplasmático , Inflamassomos/metabolismo , Monócitos/metabolismo , Receptor 2 Toll-Like/antagonistas & inibidores , Receptor 4 Toll-Like/antagonistas & inibidores , Anti-Inflamatórios não Esteroides/uso terapêutico , Biomarcadores/metabolismo , Linhagem Celular , Ácidos Docosa-Hexaenoicos/uso terapêutico , Estresse do Retículo Endoplasmático/efeitos dos fármacos , Inibidores Enzimáticos/farmacologia , Inibidores de Histona Desacetilases/farmacologia , Humanos , Imunomodulação , Inflamassomos/efeitos dos fármacos , Inflamassomos/imunologia , Interleucina-1beta/agonistas , Interleucina-1beta/metabolismo , Ligantes , Lipopeptídeos/farmacologia , Lipopolissacarídeos/toxicidade , Monócitos/efeitos dos fármacos , Monócitos/imunologia , Ácido Palmítico/efeitos adversos , Ácido Palmítico/metabolismo , Fenilbutiratos/farmacologia , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/antagonistas & inibidores , ATPases Transportadoras de Cálcio do Retículo Sarcoplasmático/metabolismo , Transdução de Sinais/efeitos dos fármacos , Tapsigargina/farmacologia , Receptor 2 Toll-Like/agonistas , Receptor 2 Toll-Like/metabolismo , Receptor 4 Toll-Like/agonistas , Receptor 4 Toll-Like/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...